Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study tracks immune clues in seniors with flu, RSV, and COVID-19

NCT ID NCT07643688

Knowledge-focused Sponsor: Fabiana Sherine Ganem dos Santos Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study follows 150 adults aged 60 and older who have a respiratory infection (flu, RSV, or COVID-19) or who test negative. Researchers will measure specific immune markers in the blood over 60 days to see how they change from early infection to recovery. The goal is to better understand the body's immune response and find clues that could lead to new treatments.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could help identify new biomarkers for predicting disease severity and point toward future treatments that boost the immune system against respiratory viruses.
What could go wrong
This is an early observational study, not a treatment trial. It only looks at markers in the blood, so it cannot prove that any new therapy works. Results may not apply to all populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 150 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jul 2026

An estimate. Start dates often move.

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

People aged 60 years or older who attended the healthcare service with flu-like symptoms.

Ages

60 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: GROUP A (Infected-Positive) * Age ≥60 years. * Symptoms compatible with viral respiratory infection (fever, cough, nasal congestion, dyspnea, etc.) between 24h and 72h from symptom onset. * Confirmed diagnosis, positive for influenza, RSV, or SARS-CoV-2 by rapid test. * Signed informed consent at visit 1. GROUP B (Non-Infected-Negative. Controls) * Age ≥60 years. * Negative diagnosis for influenza, RSV, or SARS-CoV-2 by rapid test. * Signed informed consent at visit 1. Exclusion Criteria: * Known severe immunosuppression (e.g., transplant recipient, uncontrolled HIV). * Chronic immunosuppressive treatment (except low-dose corticosteroids (≤10 mg/3 months)). * Participation in another clinical trial within the last 30 days. * Inability to comply with the visit schedule. * Immunosuppressive drugs. * Drugs indicated for treatment. * Oncology patients. * Terminal patients. * Autoimmune diseases associated with alterations in PD-L1. * Systemic lupus erythematosus (SLE). * Rheumatoid arthritis (RA). * Multiple sclerosis (MS). * Type 1 diabetes mellitus (T1DM). * Sjögren's syndrome. * Myasthenia gravis. * Autoimmune thyroiditis (Hashimoto's, Graves' disease).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute respiratory viral infection (influenza, RSV, or SARS-CoV-2) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

COVID-19 influenza respiratory syncytial virus infectious disease viral respiratory tract infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Influenza infection RSV infections SARS-CoV-2 infection

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.